Gut microbiome and metabolome: The crucial players in inflammatory bowel disease

代谢组 炎症性肠病 医学 微生物群 失调 蔷薇花 梭杆菌 溃疡性结肠炎 阿克曼西亚 人口 疾病 肠道菌群 乳酸菌 生物信息学 免疫学 内科学 拟杆菌 生物 遗传学 代谢物 环境卫生 细菌
作者
Jun Qing Yu
出处
期刊:Journal of Gastroenterology and Hepatology [Wiley]
卷期号:38 (1): 5-6 被引量:7
标识
DOI:10.1111/jgh.16098
摘要

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic inflammatory disorder in the gastrointestinal tract with a rapidly increase global incidence.1 It is now well-established that the abnormal alteration of gut microbiome, commonly referred to microbial dysbiosis, is closely associated with IBD development.2 For instance, the depletion of beneficial commensals such as Clostridium and Lactobacillus as well as their derived metabolites has been frequently observed in patients with IBD. To date, there are lots of publications studying the alteration of gut microbiome and/or metabolome in IBD. However, the gut microbiome is readily influenced by various environmental factors including diet, drugs, ethnicity, and geographical population.3 As a consequence, diverse and controversial results are reported among different studies. It is therefore of importance to summarize the findings from multiple studies, thereby minimizing the impact of inter-study variation and allowing the identification of microbes and metabolites with the most significant association with IBD. In this issue of Journal of Gastroenterology and Hepatology, Upadhyay et al. conducted a literature review on publications using amplicon sequencing to profile the gut microbiome in patients with IBD.4 Several microbial taxa that are consistently altered in IBD patients from different studies, were identified in this article. This includes the enrichment of opportunistic pathobionts including Fusobacterium and Streptococcus are enriched in IBD patients, as well as the depletion of beneficial commensals such as Clostridium, Lactobacillus, and Roseburia.5, 6 Upadhyay et al. also reported that there is no significant difference in microbiome composition between UC and CD patients.7 Of note, some microbial taxa including Bacteroides were found to have opposing changes across studies.6, 8 This may be due to the low resolution of amplicon sequencing, of which it cannot characterize microbial taxa at species level. For Bacteroides species, some of them are known probiotics (e.g. B. fragilis) while the others can be potentially pathogenic (e.g. B. ovatus). To allow comprehensive characterization, it is necessary to conduct metagenomic sequencing which has a higher taxonomical resolution, thereby facilitating identification at species or even strain level. Apart from the microbes themselves, their derivatives also play a role in inflammation. A classic example is the correlation between high-fat diet and IBD, of which the high content of dietary lipids impairs the gut barrier with increased intestinal permeability.9 This allows bacterial endotoxins particularly lipopolysaccharides to have easier access into the bloodstream, causing systemic inflammation and imbalance of lipid metabolism. An increased triglyceride level could also result in gut microbial dysbiosis.10 Consistently, Upadhyay et al. revealed the decrease of various lipid metabolites in IBD patients from different studies, implicating their reduced capability to metabolize dietary lipids.4 Of note, lipid metabolites are known to have dual roles in inflammation, especially the contrasting immunomodulatory role between monounsaturated and polyunsaturated fatty acids.11 Such complex mechanisms may therefore explain the ineffectiveness of supplementing long-chain fatty acids to treat IBD patients.12 It is also noteworthy that literatures included in the study by Upadhyay et al. profiled metabolites in different sample types (feces, serum, plasma, or colon mucosa), which may in turn lead to the inter-study variation of results.4 In comparison, the role of short-chain fatty acids (SCFAs) in IBD is less controversial. SCFAs are produced by gut bacteria during the fermentation of non-digestible polysaccharides. Acetate, propionate, and butyrate are the three most common SCFAs and they are all crucially involved in the maintenance of intestinal homeostasis. SCFAs also interact with colon epithelial cells to activate a cascade of anti-inflammatory signaling pathways.13 Indeed, Upadhyay et al. confirmed the consistent depletion of SCFAs in IBD patients from multiple studies.4 Similarly, some preclinical studies reported that SCFAs particularly butyrate could directly suppress the production of pro-inflammatory cytokines from neutrophils and other immune cells, thus suggesting the therapeutic potential of SCFA supplementation against IBD.14 Meanwhile, Upadhyay et al. also examined the abundance of amino acids including phenylalanine, leucine, valine, and lysine in IBD patients, yet their changes are greatly varied across studies.4 Such disparity may attribute to the lack of investigation on the alteration of a specific amino acid in IBD. Further studies are warranted to depict the role and mechanistic association of different amino acids with chronic inflammation. To wrap up this article, Upadhyay et al. highlighted that there is still a huge gap between the identified metabolites and their actual roles in IBD. Likewise, it remains elusive whether these microbial changes are the cause or consequence of persistent inflammation. In that case, integrated analysis on the gut microbiome and metabolome should be considered to fully unravel their mechanisms in IBD. For example, the consistent depletion of SCFAs and their bacterial producers in IBD patients therefore testifies their anti-inflammatory functions in humans. With the advance in metagenomic and metabolomic profiling, it is feasible to have a deeper understanding on the intricate relationship among gut microbes, metabolites, and the host. In addition, Upadhyay et al. also pinpointed the necessity of validation by targeted metabolomic analysis, which undoubtedly can reduce controversial findings among studies. Together, on top of the tremendous efforts that have been invested, in-depth mechanistic investigations rather than characterization of the gut microbiome and metabolome in IBD should now be of focus, thereby reducing the global socioeconomic burden brought by this disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
俊逸的平卉完成签到 ,获得积分10
刚刚
刚刚
coldspringhao发布了新的文献求助10
刚刚
雪山大地发布了新的文献求助10
刚刚
刚刚
2秒前
桐桐的应助被eh采纳,获得10
3秒前
3秒前
3秒前
陈皮泡泡糖完成签到,获得积分10
3秒前
八木发布了新的文献求助10
3秒前
小酒窝完成签到 ,获得积分10
4秒前
Hu完成签到,获得积分10
4秒前
5秒前
fan发布了新的文献求助10
5秒前
共享精神的应助被xiaogua采纳,获得10
5秒前
6秒前
香蕉觅云的应助被白青采纳,获得10
6秒前
6秒前
7秒前
思源的应助被叶子采纳,获得10
7秒前
houzhi6678完成签到,获得积分10
7秒前
爆米花的应助被MaximWang采纳,获得10
7秒前
天天快乐的应助被ai采纳,获得10
7秒前
samo发布了新的文献求助10
8秒前
王苏仑完成签到,获得积分10
8秒前
爆米花的应助被科研通管家采纳,获得10
8秒前
8秒前
SciGPT的应助被小明同学采纳,获得10
8秒前
shen的应助被科研通管家采纳,获得20
9秒前
打打的应助被科研通管家采纳,获得10
9秒前
9秒前
ding的应助被科研通管家采纳,获得10
9秒前
9秒前
cz完成签到,获得积分10
9秒前
Akim的应助被科研通管家采纳,获得10
9秒前
9秒前
9秒前
丘比特的应助被科研通管家采纳,获得20
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163835
求助须知:如何正确求助?哪些是违规求助? 9557925
关于积分的说明 21742693
捐赠科研通 7754454
什么是DOI,文献DOI怎么找? 3428350
关于科研通互助平台的介绍 2553034
邀请新用户注册赠送积分活动 2472982